Evercore ISI Group Maintains Outperform on Vera Therapeutics, Lowers Price Target to $91
Vera Therapeutics, Inc. Class A
Vera Therapeutics, Inc. Class A VERA | 0.00 |
Evercore ISI Group analyst Gavin Clark-Gartner maintains Vera Therapeutics (NASDAQ:
VERA) with a Outperform and lowers the price target from $95 to $91.
